Loading...
MACC
Projects

CORE RESEARCH PROJECTS

Dementia Prevention
Neurochemistry, Molecular Pathology and Biomarker Discovery
Research into pathways, mechanisms, and disease pathology for dementia are the focus of the MACC laboratories. The MACC is also dedicated to the discovery of novel blood-based biomarkers for Alzheimer's Disease (AD) and Vascular Cognitive Impairment (VCI).
Healthy Ageing
Dementia Neuroimaging
Neuroimaging is extremely important for the diagnosis of dementia and cognitive impairment. Brain imaging such as magnetic resonance imaging (MRI), Computed tomography (CT), positron emission tomography (PET) can provide information about the brain vasculature and structure. At the MACC we use multi-modal magnetic resonance imaging (MRI) and retinal imaging techniques to systematically study brain and blood vessel function and structure.
Memory Test
Improving the Diagnosis of Vascular Cognitive Impairment
Vascular Cognitive Impairment (VCI) is common following stroke. Currently, the MACC aims to improve the diagnosis of VCI through the Harmonization longitudinal study that follows up participants for up to 5 years.
Memory Screening
Epidemiology of Dementia in Singapore
The Epidemiology of Dementia in Singapore (EDIS) study is a population-based study, a collaboration between the MACC and the Singapore Eye Research Institute that focuses on the risk factors and prevalence of dementia and cognitive impairment in the three major Asian ethnicities of the Singaporean population.
MACC are currently conducting a variety of projects and studies. If you are interested in collaborating with us, please contact us. We are also providing coordinating and psychometric rating services for clinical studies and clinical trial, click here to see our services.

You may also follow us on twitter to get the latest updates on our work.

Here is a list of ongoing and completed clinical studies and clinical trials in MACC:

Memory Problems Clinical Studies

Ongoing
  • Etiology of Cortical Cerebral Microinfarcts and Impact on Brain Function and Long Term Outcomes
  • Translational Research in Vascular Biomarkers of Dementia: Discovery, Validation and Assessment of Clinical Utility
  • The Assessment of cnm-positive Streptococcus mutans as the Risk for Cerebral Small Vessel Disease in Cognitively Impaired Patients
  • Associations of sleep and rhythm fragmentation with beta amyloid burden in older adults
  • The SINgapore GERiatric intervention study to reduce cognitive decline and physical frailty (SINGER) Study, biomarker and health service research analyses
  • World-Wide-FINGERS-SARS-CoV-2 Survey study
Completed
  • A 78-Week NoninterventionalLongitudinal Study to Validate the Alzheimer’s Disease Assessment Scale –Cognitive Subscale (ADAS-Cog), Disability Assessment for Dementia (DAD), and Neuropsychological Test Battery (NTB) in Asian Subjects With Mild to Moderate Alzheimer’s Disease
  • Cognitive Outcome After STroke (COAST)
  • Translational Research in Dementia: Mechanisms of Diseases, Pathophysiologyand Biomarker Discovery
  • The feasibility and validation of an informant-based cognitive screening instrument in the primary healthcare setting
  • Epidemiology of Dementia in Singapore : Ethnicity and Risk Factors
  • Retinal Imaging in Dementia
  • Improving the Diagnosis of Vascular Cognitive Impairment by Prospective Longitudinal Clinical Studies by a) Improving the Diagnosis of Vascular Cognitive Impairment by Prospective Longitudinal Clinical Studies b) Dementia Neuroimaging using Multi-Modal Magnetic Resonance and Retinal Imaging
  • Cognitive Outcome After STroke -Extension (COAST-E)
  • An exploratory study to compare the differences in nutritional status between patients with mild and moderate Alzheimer's disease (AD) and cognitively intact healthy people in an Asian population
  • Preclinical and clinical investigations of neurodegeneration and age-associated cognitive impairment Project V (Amyloid Brain and Retinal Imaging studies) –ABRI
  • PET amyloid-beta imaging in MCI and dementia subjects
  • A multi-national observational study to identify treatment discontinuation rate in de novo Alzheimer’s disease patient who is newly prescribed with donepezil (Aricept®) in Asia
  • SINgapore GERiatric intervention study to reduce physical frailty and cognitive decline (SINGER) Pilot Studies
  • Ocular Markers of Alzheimer’s Disease: OMEGA Study

Memory Clinical TrialsClinical Trials

Ongoing
  • A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to EvaluateEfficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer’s Disease and ElevatedAmyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer’s Disease and Intermediate Amyloid (A3 Trial).
  • A Phase III, 20-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Trial to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin as AC-SD-03 in Subjects with Mild to Moderately Severe Probable Alzheimer's Disease and Who are Noncarriers of the APOE4 allele
  • A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease
  • A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Gantenerumab in Patients with Prodromal to Mild Alzheimer’s Disease
  • Tau-Positron emission tomography imaging and tau plasma biomarkers for the diagnosis of Alzheimer?s Disease
  • Preclinical and clinical investigations of neurodegeneration and age-associated cognitive impairment - NAV4694 for Amyloid Brain imaging, amyloid plasma biomarker and Retinal Imaging (NAV ABRI)
Completed
  • Chinese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES) Study
  • Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer's Disease
  • Randomized, double-blind, parallel-group, placebo controlled study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with an acetylcholinesterase inhibitor; Phase 3
  • A multicenter, double-blind, placebo-controlled, randomized, parallel-group phase 3 Study to Evaluate the Safety and Efficacy of Masitinib in Patients With Mild to Moderate Alzheimer's Disease
  • Randomised, double-blind, parallel-group, placebocontrolled study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with an acetylcholinesterase inhibitor; Study 3
  • A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease
  • Phase 1 Randomized, Double-blind, Dose Escalation Safety Study of MLC1501 in Healthy Subjects
  • A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects with Alzheimer’s Disease
  • Chinese Medicine Neuroaid Efficacy on Stroke recovery Extenstion (CHIMES-E) Study
  • NEURoaid II (MLC 901) Assessment in Cognitively Impaired Not Demented Subjects (NEURITES)
  • An Open-Label. Extension Study of the Effects of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia
  • A Phase 3, double blind, randomized study of RVT-101 versus placebo when added to existing stable donepezil treatment in subjects with mild to moderate Alzheimer's disease" RVT-101-3001
  • The Alzheimer’s disease THErapy with NEuroaid (ATHENE) Study : Assessing the Safety and Efficacy of Neuroaid II (MLC901) in patients with mild to moderate Alzheimer's disease stable on Cholinesterase inhibitors or Memantine: A Randomized, double blind, placebo controlled trial